Archive for month: December, 2023

Chhatarpur: In a shocking incident, a stray dog was allegedly found roaming inside the patient ward of the Chhatarpur district hospital on Thursday. The concerned authorities are probing the mattter.

A serious negligence of the Chhatarpur district hospital management has come to light as a stray dog was found roaming inside the patient wards of the hospital on Thursday. 

After the incident, the Chief Medical and Health Officer (CMHO) said that it was a serious matter and strict action would be taken against the concerned person.

“It is a very serious matter that stray dogs are roaming inside the patient ward. I will instruct the civil surgeon to take strict action against the concerned employees. There should not be such mismanagement.

According to the hospital management, there has been an influx of women patients for sterilisation operations here these days and around 80 women patients were operated on Thursday.

Meanwhile, amid the sterilisation operations in the hospital, construction works are also going on the hospital due to which there is dust near the operation theatre but no prevention arrangements were made by the hospital management.

Reacting to it, CMHO Tiwari said, “There are arrangements where the operation is being conducted in the district hospital. There are no major issues of dust but the civil surgeon can make arrangements to stop it by putting curtains. The civil surgeon is being directed to fix the disorders at earliest and there should be no such carelessness again.”

Besides, an Anganwadi ASHA worker, Sangeeta Yadav also said that there was no proper cleanliness in the hospital and there was a lot of fear of the infection.

“We encourage women from our villages and bring them here for sterilisation. After the operation, we take them home and take care of them for eight days. I want to say that attention should be paid here for cleanliness and also we Asha workers and our beneficiaries are not treated properly,” She told ANI.

“There is a lot of fear of infection among the women because of dust and the construction work going on here. We all have been informed about the problems in our respective blocks but we didn’t hear back from them yet,” the ASHA worker added.

Also Read: UCMS Professor Dr Satendra Singh conferred National Annual Award for Medical Humanities 2023

The prestigious award underscores Dr Reddy’s exceptional skills, dedication, and significant impact within the realm of surgery, particularly in the field of oncology. As an accomplished oncologist, Dr Jayachandra Reddy has played a pivotal role in advancing the understanding and treatment of cancer, contributing to both patient care and the broader medical community. The Young Surgeon of India award is a testament to his commitment to excellence, innovative practices, and noteworthy service in the domain of surgical oncology. 

Bengaluru: The National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru and the Ashraya Hastha Trust (AHT) have signed a Memorandum of Understanding (MoU) with multiple stakeholders to implement a comprehensive rural mental health programme named ”NAMAN” in two different taluks in India to test the feasibility of rolling out such a programme across the country, a press release by the Health and Family Welfare Department said on Monday.

The national launch of the programme will be held today at the Convention Centre, NIMHANS.

According to the statement, the proposed Naman programme will be completed within three years. NIMHANS will develop the road map for the overall implementation of the programme, and All India Institute of Medical Sciences (AIIMS), Rishikesh, will collaborate with NIMHANS as a sub-hub for successful implementation of the programme in Uttarakhand.

“The vision of NAMAN is to implement a comprehensive taluka-level mental health programme that incorporates mental health promotion, preventive strategies, treatment of mental disorders, and rehabilitation.

The two taluks selected to implement the programme are Munsiyari taluk of Pithoragarh district of Uttarakhand State and Belur taluk of Hassan district of Karnataka, to cater to the mental health needs of the whole population of the two taluks. The programme plans to follow a lifespan approach, which would cover the entire population from womb to tomb,” the statement further stated.

Dinesh Gundu Rao, Minister, Department of Health and Family Welfare Services, Karnataka, will grace the occasion.

A clinical-stage global biopharmaceutical company Structure Therapeutics Inc. provided a comprehensive development program update for its highly selective oral GLP-1 receptor agonist, GSBR-1290.

“We are pleased that we have achieved the objectives of our first Phase 2a clinical trial of GSBR-1290 in T2DM patients which were to demonstrate favourable safety, tolerability and efficacy results and guide our plans to further optimize the already encouraging performance of GSBR-1290,” said Raymond Stevens, PhD, Founder and CEO of Structure. “Our data demonstrated that once-daily GSBR-1290 has the potential to be a best-in-class compound and a backbone for future combinations that could address large cardiometabolic indications.”

The findings were based on a randomized, double-blind, 12-week placebo-controlled Phase 2a clinical trial. the trial enrolled a total of 94 participants, including 60 participants randomized to GSBR-1290. The T2DM cohort enrolled 54 participants, randomized to 45 mg (n=10) or 90 mg GSBR-1290 (n=26), or placebo, dosed daily.

Initially, the obesity cohort enrolled 40 people randomized to GSBR-1290 120 mg (n=24) or placebo (n=16), once once-daily. An additional 24 participants are currently being enrolled in the obesity arm as previously announced and will also be randomized 3:2 to GSBR-1290 or placebo.

The primary endpoint of the Phase 2a study is the tolerability and safety of GSBR-1290. Key secondary endpoints include a reduction in weight for both cohorts, as well as a reduction in HbA1c for the T2DM cohort.

The researchers reported the following findings:

• The majority (88 to 96%, depending on the study arm) of adverse events (AEs) reported were mild to moderate.
• There were no serious adverse events (SAEs) related to the study drug. Leading AEs were gastrointestinal-related. The two most common AEs were nausea and vomiting.
• Of the 60 participants dosed with GSBR-1290, only one participant discontinued the study due to AEs related to the study drug (none in the obesity cohort and one (2.8%) in the T2DM cohort).
• There were no cases of elevated liver enzymes in the obesity cohort. One participant in the T2DM treatment group experienced an event of elevated liver enzymes without an increase in bilirubin initially at day 8 while receiving 5 mg of the study drug. This participant was diagnosed with fatty liver disease while in the study.
• In the T2DM cohort, there was a statistically significant HbA1c reduction (- 1.01 to -1.02%, placebo-adjusted) at Week 12. The study demonstrated a statistically significant and clinically meaningful reduction in weight at Week 12 (-3.26% to -3.51%, placebo-adjusted). Weight loss continued to decrease through Week 12.
• Results of the interim analysis in the obesity cohort showed a statistically significant and clinically meaningful decrease in weight at Week 8 (-4.74%, placebo-adjusted) (table 4). Weight loss continued to decrease throughout the eight weeks of treatment.

“GSBR-1290 has demonstrated proof of concept in individuals with both obesity and T2DM, with clear effects on both weight loss and HbA1c that has the potential to increase with longer duration of treatment,” said David D’Alessio, M.D., Chief of the Division of Endocrinology and Metabolism at Duke University.

“The unmet medical need for both T2DM and chronic weight management continues to be very large, and the GLP-1 receptor is a target with considerable potential. Safe and effective oral small molecule GLP-1 receptor agonists would be a significant advance in that they could expand access for many patients for whom this is not now possible.”

A study was conducted by researchers to describe bone health and associated factors in children with severe cerebral palsy.

In a retrospective, single-centre study, the  researchers performed a comprehensive bone evaluation (including clinical, densitometric and bone biomarker assessments) of children with severe cerebral palsy.

Results:

In the  research, None of the 19 included children had a normal BMCTBLH Z score, and only one had a BMDTBLH Z score greater than −2. Six children had a BMDLS Z score greater than −2. The bone biomarker data were suggestive of excessive bone remodelling. Levels of bone remodelling markers factors and densitometric variables were not significantly related. Further Age, weight and pubertal stage were significantly related to bone mass.

The results highlights the insufficient increase in bone mass with age (probably due to excessive bone remodelling) and confirms the high prevalence of low bone mineral density in children with severe cerebral palsy. Possible preventive measures might include calcium + vitamin D supplementation and the systematic management of underweight and delayed puberty. Bone remodelling markers might be of value for follow-up.

An insufficient increase in bone mass was seen with age and high prevalence of low bone mineral densityBone biomarker data indicated excessive bone remodelling; weight and pubertal stage were also related to bone mass

Reference:

Barbier V, Goeb V, Gouron R, Fritot S, Mentaverri R, Klein C. Bone health in children with severe cerebral palsy. Front Pediatr. 2023 Nov 29;11:1264111. doi: 10.3389/fped.2023.1264111. PMID: 38094189; PMCID: PMC10716435.

Keywords:

Children, severe, Cerebral Palsy, more, likely, have, poor, bone, mineralization, Barbier V, Goeb V, Gouron R, Fritot S, Mentaverri R, Klein C, Frontiers in Pediatrics